152 related articles for article (PubMed ID: 35543550)
21. FANCI serve as a prognostic biomarker correlated with immune infiltrates in skin cutaneous melanoma.
Cai Z; Duan Y; Li W; Liu Z; Gong Z; Hong S; He X; Xuanyuan X; Chen Y; Bi X; Wang W
Front Immunol; 2023; 14():1295831. PubMed ID: 38077326
[TBL] [Abstract][Full Text] [Related]
22. DIRAS2 Is a Prognostic Biomarker and Linked With Immune Infiltrates in Melanoma.
Xue W; Zhu H; Liu H; He H
Front Oncol; 2022; 12():799185. PubMed ID: 35651810
[TBL] [Abstract][Full Text] [Related]
23. Multi-omics analysis of tumor mutation burden combined with immune infiltrates in melanoma.
Jiang F; Wu C; Wang M; Wei K; Zhou G; Wang J
Clin Chim Acta; 2020 Dec; 511():306-318. PubMed ID: 33164879
[TBL] [Abstract][Full Text] [Related]
24. Expression profile and prognostic values of LSM family in skin cutaneous melanoma.
Sun X; Zhang J; Xiao C; Ge Z
BMC Med Genomics; 2022 Nov; 15(1):238. PubMed ID: 36371223
[TBL] [Abstract][Full Text] [Related]
25. Development and validation of an immune gene set-based prognostic signature in cutaneous melanoma.
Tian Q; Gao H; Zhao W; Zhou Y; Yang J
Future Oncol; 2021 Nov; 17(31):4115-4129. PubMed ID: 34291650
[TBL] [Abstract][Full Text] [Related]
26. Analysis on tumor immune microenvironment and construction of a prognosis model for immune-related skin cutaneous melanoma.
Wu M; Wang Z; Zhang J
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2023 May; 48(5):671-681. PubMed ID: 37539569
[TBL] [Abstract][Full Text] [Related]
27. A Potential Diagnostic and Prognostic Biomarker TMEM176B and Its Relationship With Immune Infiltration in Skin Cutaneous Melanoma.
Jiang L; Yang Y; Liu F; Ma M; Gao J; Sun L; Chen Y; Shen Z; Wu D
Front Cell Dev Biol; 2022; 10():859958. PubMed ID: 35399535
[No Abstract] [Full Text] [Related]
28. Prognostic and immune-related value of STK17B in skin cutaneous melanoma.
Shi X; Zhou Q; Huang B; Xia S; Jiang Y; Fang S; Lin J
PLoS One; 2022; 17(2):e0263311. PubMed ID: 35171924
[TBL] [Abstract][Full Text] [Related]
29. Ferroptosis-related genes are candidate diagnostic and prognostic biomarkers for skin cutaneous melanoma.
Jing HY; Gu W; Tan XY; Ma YR
Biomark Med; 2022 Feb; 16(3):179-196. PubMed ID: 35057634
[TBL] [Abstract][Full Text] [Related]
30. Differential Expression of the
Hu J; Xu J; Feng X; Li Y; Hua F; Xu G
Front Cell Dev Biol; 2021; 9():700661. PubMed ID: 34631699
[TBL] [Abstract][Full Text] [Related]
31. KIF4A functions as a diagnostic and prognostic biomarker and regulates tumor immune microenvironment in skin cutaneous melanoma.
Zeng S; Wang Q; Zhou R; Wang D
Pathol Res Pract; 2024 Feb; 254():155166. PubMed ID: 38286055
[TBL] [Abstract][Full Text] [Related]
32. Development of an IFNγ response-related signature for predicting the survival of cutaneous melanoma.
Hu B; Wei Q; Li X; Ju M; Wang L; Zhou C; Chen L; Li Z; Wei M; He M; Zhao L
Cancer Med; 2020 Nov; 9(21):8186-8201. PubMed ID: 32902917
[TBL] [Abstract][Full Text] [Related]
33. The nucleosome remodeling and deacetylase complex has prognostic significance and associates with immune microenvironment in skin cutaneous melanoma.
Liu X; Wang J
Int Immunopharmacol; 2020 Nov; 88():106887. PubMed ID: 32799111
[TBL] [Abstract][Full Text] [Related]
34. Development of a biomarker signature associated with anoikis to predict prognosis and immunotherapy response in melanoma.
Wu Z; Zhang R; Bao J; Yin M; Wang X
Arch Dermatol Res; 2024 May; 316(6):219. PubMed ID: 38787413
[TBL] [Abstract][Full Text] [Related]
35. Systematic expression analysis of EAF family reveals the importance of EAF2 in melanoma.
Han W; Shen GL
Int Immunopharmacol; 2020 Nov; 88():106958. PubMed ID: 33182068
[TBL] [Abstract][Full Text] [Related]
36. Downregulation of the paired box gene 3 inhibits the progression of skin cutaneous melanoma by inhibiting c-MET tyrosine kinase : PAX3 downregulation inhibits melanoma progression.
Zhang K; Yu C; Tian R; Zhang W; Tang S; Wang G
Mol Biol Rep; 2022 Oct; 49(10):9137-9145. PubMed ID: 36057879
[TBL] [Abstract][Full Text] [Related]
37. Pan-Cancer Analysis of PARP1 Alterations as Biomarkers in the Prediction of Immunotherapeutic Effects and the Association of Its Expression Levels and Immunotherapy Signatures.
Zhang X; Wang Y; A G; Qu C; Chen J
Front Immunol; 2021; 12():721030. PubMed ID: 34531868
[TBL] [Abstract][Full Text] [Related]
38. Identification of CXCL13 as an Immune-Related Biomarker Associated with Tumorigenesis and Prognosis in Cutaneous Melanoma Patients.
Si Z; Hu H
Med Sci Monit; 2021 Jul; 27():e932052. PubMed ID: 34247183
[TBL] [Abstract][Full Text] [Related]
39. The integration of single-cell sequencing, TCGA, and GEO data analysis revealed that PRRT3-AS1 is a biomarker and therapeutic target of SKCM.
Zhang W; Xie X; Huang Z; Zhong X; Liu Y; Cheong KL; Zhou J; Tang S
Front Immunol; 2022; 13():919145. PubMed ID: 36211371
[TBL] [Abstract][Full Text] [Related]
40. Pan-cancer analysis reveals RIPK2 predicts prognosis and promotes immune therapy resistance via triggering cytotoxic T lymphocytes dysfunction.
Song J; Yang R; Wei R; Du Y; He P; Liu X
Mol Med; 2022 May; 28(1):47. PubMed ID: 35508972
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
